Capsid-Modified rAAV3 Vectors for Higher Liver Cancer Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing recombinant adeno-associated virus (rAAV) vectors exhibit varying transduction efficiencies in different cells and tissues, limiting their effectiveness in gene therapy applications, particularly for targeted delivery to human cells.
Innovation Solution
Development of capsid-modified rAAV vectors with specific amino acid substitutions at surface-exposed residues, such as Y252, Y272, Y444, Y701, Y705, Y731, S459, S663, T251, T492, K528, K533, and K545, enhancing transduction efficiency and stability while reducing immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If wild-type rAAV vectors are used for gene delivery, then the vectors can infect a variety of cell types, but the transduction efficiency varies greatly and is limited in many cells and tissues
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at surface-exposed residues of the AAV capsid protein (such as Y252, Y272, Y444, Y701, Y705, Y731, S459, S663, T251, T492, K528, K533, and K545). These localized modifications at specific positions on the capsid surface enhance transduction efficiency for particular cell types while preserving the overall ability to infect various tissues.
Solution Approach 2:
The patent employs parameter changes by systematically modifying the amino acid sequence of the capsid protein at specific residues. These parameter changes in the capsid structure alter the vector's interaction with cellular receptors and entry mechanisms, thereby optimizing transduction efficiency for target cells while maintaining broad tissue tropism.
2Reliability
If standard rAAV vectors are used, then the vectors can deliver therapeutic genetic material, but they exhibit varying transduction efficiencies that limit effectiveness in targeted delivery to human cells
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at surface-exposed residues of the AAV capsid protein (such as Y252, Y272, Y444, Y701, Y705, Y731, S459, S663, T251, T492, K528, K533, and K545). These localized modifications at specific positions on the capsid surface enhance transduction efficiency for particular cell types while preserving the overall ability to infect various tissues.
Solution Approach 2:
The patent employs parameter changes by systematically modifying the amino acid sequence of the capsid protein at specific residues. These parameter changes in the capsid structure alter the vector's interaction with cellular receptors and entry mechanisms, thereby optimizing transduction efficiency for target cells while maintaining broad tissue tropism.
3Ease of manufacture
If unmodified rAAV vectors are used, then the vectors can be produced with standard protocols, but they require higher particle numbers to achieve effective transduction
Solution Approach 1:
The patent employs parameter changes by systematically modifying the amino acid sequence of the capsid protein at specific residues. These parameter changes in the capsid structure alter the vector's interaction with cellular receptors and entry mechanisms, thereby optimizing transduction efficiency for target cells while maintaining broad tissue tropism.
Data Source
AI summary
Multi-mutated rAAV capsid proteins and viral particles incorporating the same, that can be used in viral vector-based gene therapies. Nucleic acids encoding the same, as well as methods of making and using the same for treating or ameliorating diseases or abnormal conditions in mammals.